NasdaqGS:DYNBiotechs
Dyne Therapeutics (DYN) Gets FDA Clearance With Valuation Questions Back In Focus
Dyne Therapeutics (DYN) has drawn fresh investor attention after receiving U.S. Food and Drug Administration clearance to begin a Phase 1 trial of DYNE-302 for facioscapulohumeral muscular dystrophy, a rare muscle disease without approved treatments.
See our latest analysis for Dyne Therapeutics.
At a share price of $26.25, Dyne Therapeutics has seen strong recent momentum, with a 30 day share price return of 12.08% and a 1 year total shareholder return of 135.22%, which suggests investor...